Two Sigma Investments LP Trims Holdings in CVS Health Co. (NYSE:CVS)

Two Sigma Investments LP lessened its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 46.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,709,465 shares of the pharmacy operator's stock after selling 1,511,920 shares during the period. Two Sigma Investments LP owned about 0.14% of CVS Health worth $76,738,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Whitebox Advisors LLC bought a new position in CVS Health during the fourth quarter worth about $249,000. Hall Laurie J Trustee boosted its position in CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock worth $517,000 after purchasing an additional 11,468 shares during the period. B&D White Capital Company LLC purchased a new position in CVS Health during the fourth quarter valued at approximately $417,000. Fairfax Financial Holdings Ltd. Can purchased a new position in CVS Health during the fourth quarter valued at approximately $121,742,000. Finally, Lazard Asset Management LLC grew its stake in CVS Health by 7.3% during the fourth quarter. Lazard Asset Management LLC now owns 4,290,953 shares of the pharmacy operator's stock valued at $192,617,000 after acquiring an additional 293,406 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 1.0%

Shares of CVS traded up $0.58 during mid-day trading on Friday, reaching $60.80. The company's stock had a trading volume of 8,141,495 shares, compared to its average volume of 11,329,450. The stock has a market cap of $76.91 billion, a PE ratio of 16.61, a P/E/G ratio of 0.98 and a beta of 0.60. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $72.51. The company's fifty day moving average price is $66.15 and its two-hundred day moving average price is $59.40.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.31 EPS. On average, analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.38%. CVS Health's payout ratio is 63.48%.

Insider Activity at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.22% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CVS shares. Mizuho boosted their price objective on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Robert W. Baird boosted their price objective on shares of CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Edward Jones raised shares of CVS Health from a "hold" rating to a "buy" rating in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research note on Tuesday, February 18th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, CVS Health currently has an average rating of "Moderate Buy" and an average price target of $74.94.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.